EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Rani Therapeutics Holdings's enterprise value is $157.76 Mil.
Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Rani Therapeutics Holdings's EV-to-Revenue for today is .
The historical rank and industry rank for Rani Therapeutics Holdings's EV-to-Revenue or its related term are showing as below:
During the past 5 years, the highest EV-to-Revenue of Rani Therapeutics Holdings was 209.30. The lowest was -3.86. And the median was 46.63.
RANI's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.775 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rani Therapeutics Holdings's EV-to-Revenue
For the Biotechnology subindustry, Rani Therapeutics Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's EV-to-Revenue falls into.
Rani Therapeutics Holdings's current Enterprise Value is $157.76 Mil.
Rani Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings's share price for today is $6.36.
Rani Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Rani Therapeutics Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RANI has been successfully added to your 